Preclinical evaluation of F-18 fluoroethyltriazolyl PEGstilbenes as potential PET imaging agents for Alzheimers disease

F-18 氟乙基三唑基 PEG 芪作为阿尔茨海默病潜在 PET 成像剂的临床前评估

• 批准号: nhmrc : 582402
• 负责人: A/Pr Henri Tochon-Danguy
• 金额: $ 44.89万
• 依托单位: Austin Hospital Medical Research Foundation
• 依托单位国家: 澳大利亚
• 项目类别: NHMRC Project Grants
• 财政年份: 2010
• 资助国家: 澳大利亚
• 起止时间: 2010-01-01 至 2014-12-31
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/preclinical-evaluation-f-alzheimers-disease/82173
• 关键词: Preclinical; evaluation; 18; fluoroethyltriazolyl; PEGstilbenes

Alzheimer's disease (AD) is the most common form of dementia and is becoming am ever increasing burden to the health system due to the aging of our population. Amyloid plaques are considered the hallmark of AD and a technique for their detection in vivo would be a breakthrough, not only for the diagnosis of AD but also for the development of drugs against AD. Nuclear medicine can image tissue function non-invasively. This project aims to develop new imaging agents to improve diagnosis of AD.

阿尔茨海默病（AD）是最常见的痴呆症形式，由于人口老龄化，它正成为卫生系统日益增加的负担。淀粉样斑块被认为是阿尔茨海默病的标志，在体内检测它们的技术将是一个突破，不仅对阿尔茨海默病的诊断，而且对阿尔茨海默病药物的开发。核医学可以对组织功能进行无创成像。本项目旨在开发新的显像剂以提高对AD的诊断。